Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (381-390 of 391) with videos related to

Pageof 40
Sort By:
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Nature Genetics|October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Pageof 40

Showing results (381-390 of 391) with videos related to

Sort By:
Pageof 40
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Nature Genetics|October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Pageof 40